Year None2021202020192018201720162015201420132012 11.25.2019 Iveric Bio Appoints Guangping Gao, PhD, Internationally Recognized Gene Therapy Pioneer as Chief Strategist, Gene Therapy 11.14.2019 Iveric Bio to Host a Zimura® R&D Symposium for Investors / Analysts on November 20, 2019 11.12.2019 Iveric Bio Reports Third Quarter 2019 Operational Highlights and Financial Results 11.12.2019 Iveric Bio Initiating Second Pivotal Clinical Trial of Zimura® in GA with 1Q 2020 Targeted for First Patient Enrolled 11.05.2019 Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11.04.2019 Iveric Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019 10.29.2019 Iveric Bio Appoints Abraham Scaria, PhD, as Chief Scientific Officer 10.28.2019 Iveric Bio's Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration 09.30.2019 Iveric Bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference 09.30.2019 CORRECTING and REPLACING Iveric Bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »